NEW YORK (GenomeWeb) – NantOmics has secured CLIA certification and accreditation from the College of American Pathologists for its Culver City, California laboratory.
To garner the CLIA certification, NantOmics had to demonstrate quality standards for proficiency testing, patient test management, quality control, personnel qualifications, and quality assurance.
The firm performs whole-genome sequencing, whole-transcriptome sequencing, and quantitative proteomics as part of the GPS Cancer test, providing oncologists with a comprehensive molecular profile of a patient's cancer. It also performs the OncoPlexDx proteomic panel, though that test is being replaced by the GPS test as of the end of this month, according to NantOmics' website.
NantOmics is a subsidiary of NantWorks and performs the GPS Cancer test for NantHealth, another NantWorks subsidiary. Last fall, NantOmics completed the acquisition of OncoPlex Diagnostics, which operated a CLIA-certified and CAP-accredited lab in Rockville, Maryland.
In January, NantHealth announced that Independence Blue Cross would be the first insurer to cover the GPS Cancer test.